Addressing Exclusivity Issues During the COVID-19 Pandemic and Beyond

Forthcoming, I. Glenn Cohen, Abbe Gluck, Katherine Kraschel, & Carmel Shachar, COVID-19 and the Law: Disruption, Impact and Legacy. Cambridge University Press, 2022

15 Pages Posted: 5 Aug 2021 Last revised: 18 Aug 2021

See all articles by Michael S. Sinha

Michael S. Sinha

Harvard-MIT Center for Regulatory Science; Northeastern University - School of Law; Program On Regulation, Therapeutics, And Law (PORTAL); University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL)

Sven Bostyn

University of Copenhagen - Faculty of Law

Timo Minssen

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Date Written: August 17, 2021

Abstract

Almost every aspect of the COVID-19 response, from vaccines, diagnostics, and therapeutics to medical equipment, tracking systems, software, and other innovations, are or will become subject to some form of exclusive rights. Many of these involve intellectual property rights (IPRs). By offering innovators the exclusive right to exploit their innovations while recouping the costs of research, development, and other expenditures, IPRs may incentivize the development of new technologies. But IPRs may also preclude others from important research, manufacturing, and distribution. In the same vein, these exclusionary rights allow right holders to set prices in the absence of competition. Since this may limit access to innovations that are crucial for tackling pandemics, IPRs are a key factor in pandemic response and preparedness. Consequently, they have generated much controversy around the globe.

Many of these debates have concentrated on traditional IPRs, particularly patent rights. Numerous existing patent claims cover new chemical or molecular entities. Patents are also filed for repurposed drugs and vaccine platforms (e.g., COVID-19 mRNA platforms), with separate patent protection for the vaccine and its elements, including viral particles, adjuvants, and vaccine boosters. Even in situations where no patent protection is available, many COVID-19 therapeutics and vaccines will also obtain regulatory, data, and market exclusivities. Consequently, the specific design and new areas of application for regulatory exclusivities have become an increasingly important issue in general innovation policy debates.

This chapter addresses exclusivity issues, with a particular emphasis on regulatory exclusivities for vaccines and therapeutics. We begin with a basic overview of the current regulatory exclusivity landscape in Europe and the US, followed by a discussion of current developments in COVID-19 vaccines and therapeutics. Next, we describe the influence of these technological developments on debates surrounding regulatory exclusivities while describing their relationship to other forms of exclusivities. From these assessments, we draw some lessons for market exclusivity, innovation, and access during the COVID-19 pandemic and beyond.

Note: Funding: This work was supported by the Collaborative Research Program for Biomedical Innovation Law, which is a scientifically independent collaborative research program supported by the Novo Nordisk Foundation (grant NNF17SA0027784).

Declaration of Interests: Michael S. Sinha has no competing interests to declare. Sven J.R. Bostyn has no competing interests to declare. Timo Minssen reports that he is an IP Advisory Board Member of Chr. Hansen A/S, though the company is not involved in the vaccine business and Prof. Minssen does not receive research support from the company.

Keywords: COVID-19, innovation policy, vaccines, FDA

Suggested Citation

Sinha, Michael S. and Bostyn, Sven and Minssen, Timo, Addressing Exclusivity Issues During the COVID-19 Pandemic and Beyond (August 17, 2021). Forthcoming, I. Glenn Cohen, Abbe Gluck, Katherine Kraschel, & Carmel Shachar, COVID-19 and the Law: Disruption, Impact and Legacy. Cambridge University Press, 2022, Available at SSRN: https://ssrn.com/abstract=3889894 or http://dx.doi.org/10.2139/ssrn.3889894

Michael S. Sinha (Contact Author)

Harvard-MIT Center for Regulatory Science ( email )

200 Longwood Avenue
109 Armenise Research Building
Boston, MA 02115
United States

HOME PAGE: http://hmcrs.org/people/fellows-collaborators/

Northeastern University - School of Law ( email )

416 Huntington Avenue
Boston, MA 02115
United States

Program On Regulation, Therapeutics, And Law (PORTAL) ( email )

1620 Tremont Street
Suite 3030
Boston, MA 02120
United States

HOME PAGE: http://www.portalresearch.org

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) ( email )

Karen Blixens Plads 16
Copenhagen S, 2300
Denmark

Sven Bostyn

University of Copenhagen - Faculty of Law

Karen Blixens Plads 16
Copenhagen, DK-2300
Denmark

Timo Minssen

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law ( email )

Karen Blixens Plads 16
Copenhagen, 2300
Denmark
+46 708 607517 (Phone)

HOME PAGE: http://jura.ku.dk/cebil/staff/profile/?pure=en/persons/381631

Do you want regular updates from SSRN on Twitter?

Paper statistics

Downloads
225
Abstract Views
1,282
rank
185,519
PlumX Metrics